Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Erica Palesandro"'
Autor:
Gaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, Carla Cavaliere, Sarah Scagliarini, Maria Giuseppa Vitale, Chiara Ciccarese, Giuseppe Di Lorenzo, Erica Palesandro, Vincenza Conteduca, Umberto Basso, Emanuele Naglieri, Azzurra Farnesi, Michele Aieta, Nicolò Borsellino, Leonardo La Torre, Gelsomina Iovane, Lucia Bonomi, Donatello Gasparro, Enrico Ricevuto, Michele De Tursi, Rocco De Vivo, Giovanni Lo Re, Francesco Grillone, Paolo Marchetti, Ferdinando De Vita, Claudio Scavelli, Claudio Sini, Salvatore Pisconti, Anna Crispo, Vittorio Gebbia, Antonio Maestri, Luca Galli, Ugo De Giorgi, Roberto Iacovelli, Carlo Buonerba, Giacomo Cartenì, Carmine D’Aniello
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-11 (2019)
Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluate
Externí odkaz:
https://doaj.org/article/ce45764abe174be68515afe7c66b3135
Autor:
Maria Lucia Reale, Paolo Bironzo, Valentina Bertaglia, Erica Palesandro, Gianmarco Leone, Fabrizio Tabbò, Maristella Bungaro, Marco Audisio, Annapaola Mariniello, Simonetta G. Rapetti, Rosario F. Di Stefano, Elisa Artusio, Enrica Capelletto, Paola Sperone, Adriana Boccuzzi, Marco Calandri, Alberto Perboni, Umberto Malapelle, Francesco Passiglia, Silvia Novello
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: The world, and Italy on the front lines, has experienced a major medical emergency due to the novel coronavirus outbreak. Cancer patients are one of the potentially most vulnerable cohorts of people, but data about their management are st
Externí odkaz:
https://doaj.org/article/e9ecd82886084413aaef5456723e9a96
Autor:
Lorenzo D’Ambrosio, Erica Palesandro, Marina Moretti, Giuseppe Pelosi, Alessandra Fabbri, Fabrizio Carnevale Schianca, Massimo Aglietta, Giovanni Grignani
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-6 (2017)
Abstract Background Nuclear protein in testis (NUT) midline carcinoma is a rarely diagnosed and potentially under-recognized type of squamous carcinoma that is considered one of the most aggressive human solid tumors. Alpha-fetoprotein elevation has
Externí odkaz:
https://doaj.org/article/a27cb77a1ca74e0d9cb81ea02749581c
Autor:
Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio, Carmine Dell’Aglio, Marco Basiricò, Marta Canta, Annalisa Lorenzato, Francesca Vignolo Lutati, Sandra Aliberti, Erica Palesandro, Paola Boccone, Danilo Galizia, Sara Miano, Giulia Chiabotto, Lucia Napione, Loretta Gammaitoni, Dario Sangiolo, Maria Serena Benassi, Barbara Pasini, Giovanna Chiorino, Massimo Aglietta, Giovanni Grignani
Publikováno v:
Molecular Cancer, Vol 16, Iss 1, Pp 1-15 (2017)
Abstract Background Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groo
Externí odkaz:
https://doaj.org/article/e058c6685da841f684afb510424d766a
Autor:
Ugo De Giorgi, Giovanni Bozza, Roberto Sabbatini, Maurizio Nicodemo, Massimo Aglietta, Sabrina Rossetti, Franco Morelli, Giovanni L. Pappagallo, Giovanni Re, Camillo Porta, Giorgia Razzini, Lucia Fratino, Gaetano Facchini, Michele Aieta, Alessandro D'Angelo, Francesco Carrozza, Marco Maruzzo, Orazio Caffo, Paola Ermacora, Isabella Vittimberga, Erica Palesandro, Stefania Kinspergher, Sebastiano Buti, Monica Giordano, Daniela Scapoli, Franco Nolè, Luca Galli, Claudia Mucciarini, Donatello Gasparro, Cinzia Ortega, Chiara Ciccarese, Elena Verri, Francesca Maines, Giuseppe Schepisi, Francesca Valcamonico, Roberto Iacovelli, Antonello Veccia, Vittorina Zagonel, Caterina Messina, Donata Sartori, Paolo Lippe
Publikováno v:
European Journal of Cancer. 155:56-63
Background Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen receptor translocation and signalling. The aim of this study is to assess the efficacy of their concurrent administration in the first-line treatment for met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd20c0b200a01a11d84c69122e5487a
https://doi.org/10.1016/j.ejca.2021.06.016
https://doi.org/10.1016/j.ejca.2021.06.016
Autor:
Salvatore Pisconti, Vittorio Gebbia, Michele Aieta, Erica Palesandro, Emanuele Naglieri, Donatello Gasparro, Nicolò Borsellino, Antonio Maestri, Anna Crispo, A. Farnesi, Francesco Grillone, Lucia Bonomi, Gaetano Facchini, Giovanni Re, Giacomo Cartenì, Rocco De Vivo, Sarah Scagliarini, Giuseppe Di Lorenzo, Umberto Basso, Ferdinando De Vita, Enrico Ricevuto, Gelsomina Iovane, Claudio Sini, Maria Giuseppa Vitale, Luca Galli, Carla Cavaliere, Sabrina Rossetti, Carmine D'Aniello, Michele De Tursi, Carlo Buonerba, Chiara Ciccarese, Roberto Iacovelli, Claudio Scavelli, Ugo De Giorgi, Paolo Marchetti, Vincenza Conteduca, Leonardo La Torre, Massimiliano Berretta
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-11 (2019)
Journal of Translational Medicine
Università degli studi di Foggia-IRIS
Journal of Translational Medicine
Università degli studi di Foggia-IRIS
Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluated. Accord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12acb662f5d5d700c929cd93d0d7e2f
http://link.springer.com/article/10.1186/s12967-019-2047-4
http://link.springer.com/article/10.1186/s12967-019-2047-4
Autor:
Alberto Perboni, Umberto Malapelle, Erica Palesandro, Paola Sperone, Marco Calandri, Francesco Passiglia, Enrica Capelletto, Paolo Bironzo, Maria Lucia Reale, Silvia Novello, Fabrizio Tabbò, Marco Audisio, Elisa Artusio, Maristella Bungaro, Gianmarco Leone, S.G. Rapetti, Rosario F Di Stefano, Adriana Boccuzzi, Annapaola Mariniello, Valentina Bertaglia
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Background: The world, and Italy on the front lines, has experienced a major medical emergency due to the novel coronavirus outbreak. Cancer patients are one of the potentially most vulnerable cohorts of people, but data about their management are st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae756883fb4af351280cef960511b36
http://hdl.handle.net/11588/846552
http://hdl.handle.net/11588/846552
Autor:
Rosario F Di Stefano, Elisa Artusio, Maria Lucia Reale, Marco Audisio, Erica Palesandro, Silvia Novello, Annapaola Mariniello, Fabrizio Tabbò, Maristella Bungaro, S.G. Rapetti, Gianmarco Leone, Enrica Capelletto, Simona Carnio, Paolo Bironzo, Valentina Bertaglia, Paola Sperone, Francesco Passiglia
Publikováno v:
Critical Reviews in Oncology/Hematology
Graphical abstract
Highlights • Survey to evaluate outpatient management and therapeutic decisions for NSCLC patients. • Delay of lung cancer diagnosis and a dramatic decrease of patients’ accrual within clinical trials. • Major changes
Highlights • Survey to evaluate outpatient management and therapeutic decisions for NSCLC patients. • Delay of lung cancer diagnosis and a dramatic decrease of patients’ accrual within clinical trials. • Major changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc6b872cc3f15066cf10e65be4031ca
https://doi.org/10.1016/j.critrevonc.2020.103189
https://doi.org/10.1016/j.critrevonc.2020.103189
Autor:
Sabrina Rossetti, Donatello Gasparro, Michele Aieta, Carlo Messina, Roberto Iacovelli, Maurizio Nicodemo, Marianna Macerelli, Orazio Caffo, Claudia Mucciarini, Donata Sartori, Erica Palesandro, Franco Nolè, Lucia Fratino, Ugo De Giorgi, Francesco Carrozza, Franco Morelli, Vittorina Zagonel, Daniela Scapoli
Publikováno v:
Journal of Clinical Oncology. 38:123-123
123 Background: CHEIRON trial was a phase II study which randomized previously untreated mCRPC pts to receive D 75 mg/m2 IV d1 q3w for 8 courses alone or plus E 160 mg PO daily. As per protocol, E was administered in experimental arm for only 24 wks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f98e1b94b1a6e2d9471b8ef0bc5c51f
https://doi.org/10.1200/jco.2020.38.6_suppl.123
https://doi.org/10.1200/jco.2020.38.6_suppl.123
Autor:
Franco Morelli, Cristina Masini, Giuseppe Fornarini, Andrea Sbrana, Beatrice Detti, Roberto Iacovelli, Ugo De Giorgi, Alessandra Mosca, Erica Palesandro, Federico Paolieri, Elisa Biasco, Daniele Santini, Claudia Caserta, Luca Galli
Publikováno v:
Anticancer research. 38(8)
BACKGROUND/AIM The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6feb41b73913860a385007c80e96aff3
https://pubmed.ncbi.nlm.nih.gov/30061269
https://pubmed.ncbi.nlm.nih.gov/30061269